A Phase 2, Real-time Assessment of Combination Therapies in Immuno-Oncology Study in Participants With Advanced Renal Cell Carcinoma (FRACTION-RCC)
Phase of Trial: Phase II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs BMS 986016 (Primary) ; Nivolumab (Primary) ; Ipilimumab
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms FRACTION-RCC
- Sponsors Bristol-Myers Squibb
- 30 Jun 2017 Planned number of patients changed from 650 to 200.
- 07 Feb 2017 Status changed from not yet recruiting to recruiting.
- 21 Dec 2016 New trial record